Table 1. Correlation between miR-652-5p expression and clinicopathological parameters of OSCC patients.
| Characteristics | Training group (n = 93) | Test group (n = 100) | ||||
|---|---|---|---|---|---|---|
| Low (n = 72) | High (n = 21) | P | Low (n = 74) | High (n = 26) | P | |
| Gender | ||||||
| Male | 59 (76.6%) | 15 (23.4%) | 0.293 | 62 (74.7%) | 21 (25.3%) | 0.316 |
| Female | 13 (68.4%) | 6 (28.6%) | 10 (66.7%) | 5 (23.3%) | ||
| Age | ||||||
| ≤60 | 22 (81.5%) | 5 (18.5%) | 0.549 | 25 (73.5%) | 9 (26.5%) | 0.939 |
| > 60 | 50 (75.8%) | 16 (24.2%) | 49 (74.2%) | 17 (25.8%) | ||
| Tumor size | ||||||
| < 5 cm | 41 (80.4%) | 10 (19.6%) | 0.450 | 50 (76.9%) | 15 (23.1%) | 0.364 |
| ≥ 5 cm | 31 (73.8%) | 11 (26.2%) | 24 (68.6%) | 11 (31.4%) | ||
| Tumor stagesa | ||||||
| T1+ T2 | 16 (72.2%) | 6 (27.3%) | 0.605 | 14 (60.9%) | 9 (39.1%) | 0.102 |
| T3+ T4 | 50 (78.1%) | 14 (21.9%) | 60 (77.9%) | 17 (22.1%) | ||
| Histological grade | ||||||
| Well/moderate | 57 (77.0%) | 17 (23.0%) | 0.858 | 62 (75.6%) | 20 (24.4%) | 0.433 |
| Poor/NS | 15 (78.9%) | 4 (21.1%) | 12 (66.7%) | 6 (33.3%) | ||
| Lymph node metastasis | ||||||
| Negative | 27 (60.0%) | 18 (40.0%) | 0.000 | 39 (66.1%) | 20 (33.9%) | 0.031 |
| Positive | 45 (93.8%) | 3 (6.2%) | 35 (85.4%) | 6 (14.6%) | ||
| Clinical stagesa | ||||||
| I + II | 30 (62.5%) | 18 (37.5%) | 0.000 | 36 (62.1%) | 22 (37.9%) | 0.000 |
| III + IV | 38 (77.3%) | 2 (22.7%) | 38 (90.5%) | 4 (9.5%) | ||
aNumbers might be less than the total number if missing data.